Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jazz Pharmaceuticals

- PMLiVE

PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19

Early study results published in peer-reviewed journal Science

- PMLiVE

Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Drug combination failed to improve overall survival rate

- PMLiVE

Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs

Collaboration will focus on two cancer targets on the Ras/Raf/MAP kinase pathway

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

AstraZeneca AZ

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Will go head-to-head with rival Roche's Tecentriq if approved

- PMLiVE

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting

- PMLiVE

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

- PMLiVE

Jazz Pharma bags FDA approval for rare disease drug

Defitelio given the green light to treat patients who develop severe hepatic VOD

- PMLiVE

PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

Cancer drug could be approved in the US within months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links